Immunotherapy: Separating Facts from Fiction
Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium. “The impact of immunotherapy, at least for PD-1 [programmed death-1] checkpoint blockade, is primarily on survival,†he said. “Response [ Read More ]